Compare TKNO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | NKTR |
|---|---|---|
| Founded | 1996 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.1M | 2.2B |
| IPO Year | 2021 | 1996 |
| Metric | TKNO | NKTR |
|---|---|---|
| Price | $6.94 | $67.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $146.67 |
| AVG Volume (30 Days) | 168.0K | ★ 511.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $40,520,000.00 | ★ $307,711,000.00 |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.35 | ★ 86.00 |
| 52 Week Low | $1.91 | $33.40 |
| 52 Week High | $7.84 | $109.00 |
| Indicator | TKNO | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 34.77 |
| Support Level | $4.87 | $64.28 |
| Resistance Level | $7.66 | $76.63 |
| Average True Range (ATR) | 0.36 | 2.75 |
| MACD | -0.11 | -0.86 |
| Stochastic Oscillator | 43.51 | 7.41 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.